InvestSMART

SomnoMed Limited (ASX: SOM) - Share Price

Current share price for SOM : $0.510 0.045 (8.11%)+

SomnoMed Limited (SOM), an ASX-listed company, is a Company that is engaged in commercialisation of the SomnoDent Mandibular Advancement Splint and other oral devices for sleep related disorders in Australia and overseas.

SOM General Information +

ASX Code SOM
Website http://www.somnomed.com
Industry/Sector Health Care Equipment
Market Cap ($M) 111
SOM Share Price $0.510
Day High $0.528
Day Low $0.500
Last Close $0.555
SOM Share Price Movement $0.05 ( 8.11% )
Prices as at 12:05, 22 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

SomnoMed Limited (SOM) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from SomnoMed Limited (SOM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

SomnoMed Limited (SOM) price-sensitive announcements

SOM - Investor presentation
SomnoMed Limited's investor presentation for the first half of fiscal year 2026 highlights
SomnoMed Limited (SOM)
27 Feb 2026 | 8:13 AM
SOM - Half year results announcement FY26
SomnoMed Limited announced its half-year results for 1H FY26, reporting a record revenue o
SomnoMed Limited (SOM)
27 Feb 2026 | 8:12 AM
SOM - Half Yearly Report and Accounts
SomnoMed Limited reported a net profit after tax of $792,000 for the half-year ended 31 De
SomnoMed Limited (SOM)
27 Feb 2026 | 8:12 AM
SOM - AGM Investor Presentation & addresses
SomnoMed Limited's 2025 Annual General Meeting (AGM) highlighted the company's strategic f
SomnoMed Limited (SOM)
27 Nov 2025 | 12:14 PM

SomnoMed Limited (SOM) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Becoming a substantial holder 18 Jun 2026 4:38PM $0.550 $0.510 fallen by 7.27%
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Notification regarding unquoted securities - SOM 20 Mar 2026 5:05PM $0.638 $0.510 fallen by 20%
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Application for quotation of securities - SOM 18 Mar 2026 6:52PM $0.665 $0.510 fallen by 23.31%
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Application for quotation of securities - SOM 9 Mar 2026 4:41PM $0.650 $0.510 fallen by 21.54%
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Notification of cessation of securities - SOM 9 Mar 2026 4:38PM $0.650 $0.510 fallen by 21.54%
SomnoMed Limited (SOM)
ORDINARY FULLY PAID
 Health Care $112 Investor presentation 27 Feb 2026 8:13AM $0.660 $0.510 fallen by 22.73%

SOM Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 $1.70 41.70% 32.60 0.00 0.00% 0.0%
2026F C2 $1.20 -173.60% 46.30 0.00 0.00% 0.0%
2025A -$3.46 -$1.60 -78.60% 0.00 0.00 0.00% 0.0%

SOM Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Cochlear Limited (COH) $7,474M 0.0171 -0.1883 0.0862 19.0983 23.5286 21.6622 3.76% 3.03% 3.24%
Fisher & Paykel Healthcare Corporation Limited (FPH) $18,729M 0.1388 0.1365 0.1883 48.2232 42.4295 35.7071 1.36% 1.46% 1.65%
ResMed Inc. (RMD) $15,136M 0.3087 9.7634 0.0805 182.2558 16.9329 15.6712 1.26% 1.33% 1.40%
SomnoMed Limited (SOM) $120M -0.7861 0.0000 0.4167 0.0000 45.8333 32.3529 0.00% 0.00% 0.00%

SOM Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 49.80 2.54 0.67
Market 0.29 13.20 1.17 0.67
Sector 0.57 22.30 1.64 2.71

SOM Directors

Name Position Start Date
Ms Amrita Blickstead Executive Director, Joint CEO 24 Aug 2020
Ms Karen Borg Executive Director, Joint CEO 26 Nov 2020
Mr Gaetano (Guy) Alfred Gerrard Russo Non-Executive Chairman, Non-Executive Director 24 Aug 2020
Mr Michael Gordon Non-Executive Director 24 Aug 2020
Mr Andrew Price Non-Executive Director 17 Jan 2025
Mr Benjamin(Ben) Gisz Non-Executive Director 8 Oct 2024

SomnoMed Limited (SOM) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
16 Sep 2025 GISZ, Benjamin(Ben) Sell Indirect Shares 13,211,430 $0.700 $9,248,001.000
5 Dec 2024 RUSSO, Gaetano (Guy) Buy Indirect Shares 665,000 $0.443 $294,661.500
23 Sep 2024 BORG, Karen Buy Indirect Shares 12,238 $0.440 $5,384.720

See all changes in directors' interest & trades for SomnoMed Limited (SOM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SOM Management

Name Position
Ye-Fei Guo Chief Financial Officer
Terence Anthony Flitcroft Company Secretary

SOM Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in SomnoMed Limited (SOM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
67,716,079 (31.33%) TDM Asset Management Pty Ltd and its associates
31,395,623 (14.53%) National Nominees Ltd
17,800,389 (8.24%) FIL Limited and the entities
17,605,237 (8.15%) Dottie Investments Pty Limited

SOM Calendar of Events

Date Event
26 February 2027 Report (Interim)
27 August 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.